In 2016, Illumina’s stock dropped nearly 30%. This year has already been much better for the genomic sequencing leader, with shares climbing 25% in less than a month. That nice rebound could be at risk on January 31 when Illumina announces its fourth-quarter and full-year 2016 results. Here are three things you’ll want to watch with the company’s update.
HiSeq system sales
Illumina reported disappointing results in the third quarter. Lower-than-expected sales of its high-throughput systems was the primary culprit. There were two reasons behind the lower sales last quarter.
